• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

analysis of the effect of changes in the microenvironment around cancer on renal cancer stem cells: development of new treatment strategies

Research Project

Project/Area Number 18K09170
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 56030:Urology-related
Research InstitutionNagasaki University

Principal Investigator

Ohba Kojiro  長崎大学, 病院(医学系), 講師 (20593825)

Co-Investigator(Kenkyū-buntansha) 望月 保志  長崎大学, 病院(医学系), 准教授 (40404256)
宮田 康好  長崎大学, 医歯薬学総合研究科(医学系), 准教授 (60380888)
Project Period (FY) 2018-04-01 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Keywords腎細胞癌 / 癌免疫 / TNF-α / TGF-β / マクロファージ / ローヤルゼリー / 転移性腎癌 / 治療効果予測因子 / MSCF / 腎癌 / 腫瘍免疫 / 癌微小環境 / 微小環境 / リンパ球 / 細胞培養 / 倫理委員会 / データベース
Outline of Final Research Achievements

When we examined the relationship between histological features and malignant behavior in RCC microenvironment, NK cells, macrophages and mast cells were associated with malignant potential of RCC. Furthermore, when we investigated the roles of TNF-α, TGF-β, IL-6, and macrophage colony stimulating factor (MSCF) as chemokines expressed in the serum of patients treated with drug, it was suggested that TNF-α was associated with tumor growth, and TGF-β was involved in promoting treatment-related adverse events such as anorexia and malaise. On the other hand, it was suggested that the expression of MSCF is involved in the decrease of fatigue mediated by IL-6. It was also suggested that serum albumin and neutrophil /lymphocyte ratio may be predictors of therapeutic effect.

Academic Significance and Societal Importance of the Research Achievements

腎癌の微小環境において、免疫関連細胞が癌の悪性度と関与していることが示されたことにより、近年腎癌治療の主流となっている癌免疫療法の治療効果予測に有効な因子が浮かび上がった。これらの因子は、癌免疫療法による治療効果を予測できるバイオマーカーになりうる可能性がある。同様に有害事象の発現に関与する因子も示されたことから、癌治療を行う前にバイオマーカーの発現を確認することにより、多岐にわたる腎癌治療レジメンから、適切な治療法を選択する一助になりうる可能性が示唆される。

Report

(5 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Research-status Report
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (19 results)

All 2022 2021 2020 2019 2018

All Journal Article (8 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 5 results,  Open Access: 1 results) Presentation (11 results) (of which Int'l Joint Research: 2 results,  Invited: 3 results)

  • [Journal Article] Alternative Treatment with Every-Other-Day Dosing of Sunitinib for Metastatic Renal Cell Carcinoma: Extended Follow-Up.2022

    • Author(s)
      Ohba K, Miyata Y, Mitsunari K, Matsuda T, Mukae Y, Nakamura Y, Matsuo T, Sakai H.
    • Journal Title

      Urologia Internationalis

      Volume: 19 Issue: 6 Pages: 1-7

    • DOI

      10.1159/000520652

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed
  • [Journal Article] 転移性腎癌に対する薬物療法の展望.2021

    • Author(s)
      大庭康司郎, 宮田康好, 酒井英樹.
    • Journal Title

      泌尿器科

      Volume: 14 Pages: 123-130

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Pathological and Pharmacological Roles of Mitochondrial Reactive Oxygen Species in Malignant Neoplasms: Therapies Involving Chemical Compounds, Natural Products, and Photosensitizers.2020

    • Author(s)
      Miyata Y, Mukae Y, Harada J, Matsuda T, Mitsunari K, Matsuo T, Ohba K, Sakai H.
    • Journal Title

      Molecules

      Volume: 25 Issue: 22 Pages: 5252-5252

    • DOI

      10.3390/molecules25225252

    • Related Report
      2020 Research-status Report
  • [Journal Article] Relationship Between Stage-specific Embryonic Antigen-4 and Anti-cancer Effects of Neoadjuvant Hormonal Therapy in Prostate Cancer2020

    • Author(s)
      YUNO TSUTOMU、MIYATA YASUYOSHI、MATSUO TOMOHIRO、MUKAE YUTA、OTSUBO ASATO、MISTUNARI KENSUKE、OHBA KOJIRO、SUDA TETSUJI、SAITO SEIICHI、SAKAI HIDEKI
    • Journal Title

      Anticancer Research

      Volume: 40 Issue: 10 Pages: 5567-5575

    • DOI

      10.21873/anticanres.14569

    • Related Report
      2020 Research-status Report
  • [Journal Article] Oral intake of royal jelly improves anti?cancer effects and suppresses adverse events of molecular targeted therapy by regulating TNF?α and TGF?β in renal cell carcinoma: A preliminary study based on a randomized double?blind clinical trial2020

    • Author(s)
      Miyata Yasuyoshi、Araki Kyohei、Ohba Kojiro、Mastuo Tomhiro、Nakamura Yuichiro、Yuno Tsutomu、Mukai Yuta、Otsubo Asato、Mitsunari Kensuke、Mochizuki Yasushi、Sakai Hideki
    • Journal Title

      Molecular and Clinical Oncology

      Volume: 13 Pages: 29-29

    • DOI

      10.3892/mco.2020.2099

    • Related Report
      2020 Research-status Report
  • [Journal Article] QOL向上をめざした泌尿器がん治療 QOL向上を目指した泌尿器がん治療 腎癌の薬物治療2019

    • Author(s)
      大庭康司郎、宮田康好、松尾朋博、酒井英樹
    • Journal Title

      西日本泌尿器科

      Volume: 81 Pages: 128-133

    • Related Report
      2019 Research-status Report
    • Peer Reviewed
  • [Journal Article] QOL向上を目指した泌尿器がん治療 -腎癌の薬物療法―2019

    • Author(s)
      大庭 康司郎、宮田 康好、松尾 朋博、酒井 英樹
    • Journal Title

      西日本泌尿器科学会雑誌

      Volume: 81 Pages: 128-133

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Journal Article] Oral Intake of Royal Jelly Has Protective Effects Against Tyrosine Kinase Inhibitor-Induced Toxicity in Patients with Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled Trial.2018

    • Author(s)
      Araki K, Miyata Y, Ohba K, Nakamura Y, Matsuo T, Mochizuki Y, Sakai H.
    • Journal Title

      Medicines

      Volume: 6 Issue: 1 Pages: 1-11

    • DOI

      10.3390/medicines6010002

    • Related Report
      2018 Research-status Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] 腎癌の最新治療 Ipilimumab + nivolumab 併用療法2021

    • Author(s)
      大庭康司郎
    • Organizer
      第36回腎移植・血管外科研究会
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] YAP expression plays important roles in malignant aggressiveness by regulating the infiltration of CD57+ natural killer cells, CD68+ macrophages, and mast cells and the expression of VEGF-A and PD-L1 in clear cell renal cell carcinoma.2021

    • Author(s)
      Ohba K., Miyata Y., Harada J., Matsuda T., Kondo T., Otsubo A., Mukae Y., Ito H., Kurata H., Mitsunari K., Matsuo T., Mochizuki Y., Sakai H.
    • Organizer
      The 116th American Urological Association
    • Related Report
      2021 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Ipilimumab + Nivolumab の立場から考える1stLineの薬剤選択2021

    • Author(s)
      大庭康司郎
    • Organizer
      第51回腎癌研究会
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] ICI時代における 当科のmRCC治療戦略2020

    • Author(s)
      大庭康司郎
    • Organizer
      第72回西日本泌尿器科学会総会
    • Related Report
      2020 Research-status Report
    • Invited
  • [Presentation] 転移性腎細胞がんに対するスニチニブ隔日投与の長期フォローアップ成績2020

    • Author(s)
      大庭康司郎、迎祐太、中西裕美、光成健輔、松尾朋博、宮田康好、酒井英樹
    • Organizer
      第58回日本癌治療学会学術総会
    • Related Report
      2020 Research-status Report
  • [Presentation] Case study of inferior vena caval tumor thrombus in patients with renal cell carcinoma2019

    • Author(s)
      Kojiro Ohba, Hiroki Kurata, Yuta Mukae, Yuichiro Nakamura, Hiromi Nakanishi, Yuji Sagara, Tomohiro Matsuo, Yasushi Mochizuki, Yasuyoshi Miyata, Hideki Sakai
    • Organizer
      第50回腎癌研究会
    • Related Report
      2019 Research-status Report
  • [Presentation] 当科におけるaxitinibの治療成績2019

    • Author(s)
      迎祐太, 大庭康司郎, 上田康史, 中村裕一郎, 相良祐次, 松尾朋博, 望月保志, 宮田康好, 酒井英樹
    • Organizer
      第107回日本泌尿器科学会総会
    • Related Report
      2019 Research-status Report
  • [Presentation] 初期治療として腎摘除を施行しなかった腎細胞癌症例の臨床的検討2018

    • Author(s)
      大庭 康司郎、原田 淳樹、荒木 杏平、中西 裕美、相良 祐次、松尾 朋博、望月 保志、宮田 康好、酒井 英樹
    • Organizer
      第106回日本泌尿器科学会総会
    • Related Report
      2018 Research-status Report
  • [Presentation] Initial experience of nivolumab treatment for patients with metastatic renal cell carcinoma.2018

    • Author(s)
      Kojiro Ohba, Hidenori Ito, Yuta Mukae, Yuichiro Nakamura, Hiromi Nakanishi, Yuji Sagara, Tomohiro Matsuo, Yasushi Mochizuki, Yasuyoshi Miyata, Hideki Sakai
    • Organizer
      第56回日本癌治療学会学術総会
    • Related Report
      2018 Research-status Report
  • [Presentation] Nivolumabによるimmuno-related adverse events(irAE)の経験2018

    • Author(s)
      大庭 康司郎、松田 剛、中西 裕美、安田 拓司、相良 祐次、松尾 朋博、望月 保志、宮田 康好、酒井 英樹
    • Organizer
      第49回腎癌研究会
    • Related Report
      2018 Research-status Report
  • [Presentation] Intake of royal jelly prevents sunitinib-induced appetite loss in patients with renal cell carcinoma: Correlation with serum levels of transforming growth factor-β and macrophage colony-stimulating factor.2018

    • Author(s)
      Kojiro Ohba, Yasuyoshi Miyata, Yuichiro Nakamura, Kyohei Araki, Takuji Yasuda, Yuji Sagara, Tomohiro Matuso, Yasushi Mochizuki, Hideki Sakai
    • Organizer
      113th AUA annual meeting
    • Related Report
      2018 Research-status Report
    • Int'l Joint Research

URL: 

Published: 2018-04-23   Modified: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi